Hengrui Medicine to launch A-share buyback for employee stock plan

Jiangsu Hengrui Medicine announced a plan to repurchase its A-shares using company funds, with a total value between RMB 1 billion and RMB 2 billion. The buyback, intended for an A-share employee stock ownership plan, will be conducted via centralized bidding transactions over a period of up to 12 months from the board's approval, at a maximum price of RMB 90.85 per share.

The company will hold its first extraordinary general meeting of 2025 on September 16, 2025, to seek shareholder approval for the A-share employee stock ownership plan and its management. Shareholder voting will be available both in person and online through the Shanghai Stock Exchange network.

Certain directors and executives have disclosed a plan to reduce their holdings, but these are separate from the buyback, which has been confirmed to have no impact on the company's continuous operations, financial stability, or control.